NCT06792643View on ClinicalTrials.gov

Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

October 29, 2025

Study Completion Date

December 31, 2025

Conditions
Cardiogenic ShockExtracorporeal Membrane Oxygenation ComplicationPlatelet Dysfunction
Interventions
DRUG

Cangrelor

Cangrelor will be started without bolus at a low dose of 0.125 mcg/kg/min and titrated (by 0.125 mcg/kg/min steps) based on the results of platelet function assay to guarantee effective platelet P2Y12 pathway inhibition.

Trial Locations (1)

20132

RECRUITING

IRCCS San Raffaele Hospital, Milan

All Listed Sponsors
lead

IRCCS San Raffaele

OTHER